Skip to main content

2021 Review Course Learning Objectives and CME

Intended Audience

The ASPHO Review Course is designed for physicians preparing for the American Board of Pediatrics (ABP) examination for initial certification in pediatric hematology/oncology as well as fellows in training and practitioners providing care for pediatric patients with cancer and blood disorders who are seeking a comprehensive review and update of key concepts in the field.

Learning Objectives

As a result of attending this course, participants should be able to

  1. describe the basic pathophysiology of hematologic disease and cancer in infants, children, and adolescents, including molecular and cellular biology, the genetic and biochemical basis of disease, and the fundamentals of morphology and disease classification
  2. discuss the differential diagnosis, management, and outcomes of the hematologic disorders and malignancies encountered in practice by pediatric hematology/oncology specialists
  3. explain fundamental concepts of biostatistics, epidemiology and outcomes analysis, and engagement in scholarly activities as these areas apply to the field of pediatric hematology/oncology
  4. analyze the principles and practice of stem cell transplantation, transfusion medicine, and supportive care in children with hematologic disease and cancer, along with the basic principles of immunology and the most common immunologic disorders encountered by the hematologist
  5. prepare for the hematology/oncology subboard examination offered by the ABP and subsequent MOCA-Peds requirements.

Continuing Medical Education (CME)

The American Society of Pediatric Hematology/Oncology (ASPHO) will offer CME credit for those sessions attended and evaluated. A certificate will be issued upon completion of the evaluation.

The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 33.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASPHO offers its course evaluation in an online format that can be accessed by visiting www.aspho.org/course. The online evaluation may be completed during the course or after attendees have returned home. Participants receive their certificates immediately when they submit their evaluation. We encourage all attendees to complete their evaluation regardless of whether they are seeking CME credit.

ASPHO offers its course evaluation in an online format that will be available after the course. The online evaluation may be completed during or after the course. Participants receive their certificates upon completion of their evaluation. We encourage all attendees to complete their evaluation regardless of whether they are seeking CME credit.

Disclosure

ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The ASPHO Accreditation Subcommittee of the Education Committee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.

Speaker Disclosures:

No relevant financial relationships and no discussion of off-label drug use:

Michael Anderson, Rachel Bercovitz, Katharine Brock, Karen Effinger, Jason Fangusaro, Mark Fleming, Melissa Frei-Jones, Emily Greengard, Paul Harker-Murray, Jennifer Kesselheim, Elizabeth Mullen, Lauren Pommert, Carlos Rodriguez-Galindo, and Guy Young.

No relevant financial relationships; off-label drug use discussed:

Carl Allen, Elizabeth Fox, Cindy Neunert, Sung-Yun Pai, and David Walterhouse.

Relevant financial relationships and no discussion of off-label drug use:

Rachael Grace—Agios Pharmaceuticals, research funding; Julia Meade—AstraZeneca: Advisory Board, honorarium; Matthew Oberley—Caris Life Sciences: Executive Medical Director; Michael Pulsipher—Novartis: Steering Committee and Advisory Board, paid for time spent, Bellicum: educational talk, honorarium, Miltenyi: study support, honorarium, Adaptive: study support, paid for time spent, Jasper Therapeutics: consultant, paid for time spent; Zora Rogers—Novartis: consultant, honorarium.

Relevant financial relationships; off-label drug use discussed:

Denise Adams—Novartis: consultant, compensation, Venthura: consultant, compensation; Patrick Brown—Novartis: Scientific Advisory Board, honorarium, Servier: consulting, honorarium, Jazz: consulting, honorarium, Takeda: Scientific Advisory Board, honorarium; Mignon Loh—MediSix Therapeutics, consultant, honorarium; Kenneth McClain—SOBI Pharmaceuticals: Medical Advisory Board, honorarium; Sarah O’Brien—Bristol Myers Squib: study chair, salary support; Jacquelyn Powers—American Regent: site PI, research funding to institution.

Review Course Committee Disclosures:

No relevant financial relationships:

Nobuko Hijiya, Alex George, Julie Krystal, Sajad Khazal, Devang Pastakia, Anthony Audino, Ibrahim Ahmed, and Kayelyn Wagner.

Relevant financial relationships:

Paul Harker-Murray—Regeneron Pharmaceutical: consultation fee; Cindy Neunert—Sanofi-Genzyme: consultation fee; Jonathan Fish—Daiichi Sankyo: data monitoring committee membership, honorarium, Alexion Pharmaceuticals: data monitoring committee membership, honorarium; Stewart Goldman—AstraZeneca: speakers bureau, honorarium; Julia Meade—AstraZeneca: advisory board, honorarium; Michael A. Pulsipher—2202, 2205, and 2206 studies of CTL019: steering committee member, honorarium, Novartis: advisory board member, honorarium, Bellicum: speaker, honorarium, Milenti: speaker, honorarium, Jasper Therapeutics: consultant, honorarium.

Accreditation Subcommittee:

No relevant financial relationships:

Glen Lew, Kate Mazur, Mary-Jane Hogan, Karen Lewing, Tanya Brown, Seethal Jacob, Cathleen Cook, Chandrika Gowda, and Mukta Sharma.

Staff:

No relevant financial relationships:

Cassie McGarigle, Dominic Sawaya, and Ryan Wilkinson.

Disclaimer

The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.

Review Course Committee

The committee is responsible for the course content, and faculty recruitment and development, with attention to the American Board of Pediatrics subspecialty topic content, feedback from participants and changing requirements of maintenance of certification. The committee also directs the online review course program. View the 2021 Review Course Committee.